Johnson & Johnson beats earnings estimates on strength of Tremfya and Darzalex
Johnson & Johnson exceeded Wall Street estimates for second-quarter sales and profit, driven by strong demand for immunology drug Tremfya and cancer treatment Darzalex, offsetting erosion in other product lines.
·1 source
